COMPARATIVE ELECTROPHYSIOLOGIC FINDINGS BETWEEN RESPONDERS AND NONRESPONDERS TO CLASS-III ANTIARRHYTHMIC DRUGS AMONG PATIENTS WITH VENTRICULAR TACHYARRHYTHMIA
N. Naitoh et al., COMPARATIVE ELECTROPHYSIOLOGIC FINDINGS BETWEEN RESPONDERS AND NONRESPONDERS TO CLASS-III ANTIARRHYTHMIC DRUGS AMONG PATIENTS WITH VENTRICULAR TACHYARRHYTHMIA, Japanese Heart Journal, 39(3), 1998, pp. 307-319
Electrophysiologic testing was performed in 31 patients with ventricul
ar tachycardia (21 cases) and fibrillation (10 cases) to characterize
the electrophysiologic properties of patients responding or not respon
ding to therapy with class III antiarrhythmic drugs. At the baseline,
there were no differences among the patients in the monomorphic VT cyc
le length (CL), block CL or the width of the zone of entrainment. Vent
ricular tachyarrhythmias after the administration of class III drugs (
sotalol: 9, amiodarone: 15 and E-4031/MS-551: 7) were inducible (nonre
sponders) in 17 patients and non-inducible (responders) in 14 (45%). T
he class III drugs prolonged the sinus cycle length (SCL), QT interval
and right ventricular effective refractory period (VERP), but had lit
tle effect on ventricular conduction time in the responders and non-re
sponders. The SCL, QT interval and VERP at the three drive cycle lengt
hs of 600, 400 and 300 msec were significantly longer in the responder
s than in the non-responders, but the class III drug action on VERP sh
owed a reverse use-dependency. Isoproterenol administered to the respo
nder did not fully reverse the class III antiarrhythmic drug-induced p
rolongation of QT, QTc and VERP, which remained significantly prolonge
d compared to the baseline values. Furthermore, when the VERP after th
e administration of class III drugs were greater than 270, 250 and 240
msec at the three drive cycle lengths of 600, 400 and 300 msec, respe
ctively, it was associated with the non-inducibility of VT/VF. Though
the precise mechanism of the drug efficacy is not yet known, these obs
ervations help to clarify the ability of class III drugs to prevent th
e induction of ventricular tachyarrhythmia.